Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer

BACKGROUND Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle‐invasive bladder cancer despite the lack of Level I evidence in this setting. METHODS Data were collected using an electronic data‐capture platform from 28 international centers. Eligible patients had cli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2015-08, Vol.121 (15), p.2586-2593
Hauptverfasser:	Galsky, Matthew D., Pal, Sumanta K., Chowdhury, Simon, Harshman, Lauren C., Crabb, Simon J., Wong, Yu‐Ning, Yu, Evan Y., Powles, Thomas, Moshier, Erin L., Ladoire, Sylvain, Hussain, Syed A., Agarwal, Neeraj, Vaishampayan, Ulka N., Recine, Federica, Berthold, Dominik, Necchi, Andrea, Theodore, Christine, Milowsky, Matthew I., Bellmunt, Joaquim, Rosenberg, Jonathan E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use bladder cancer Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - pathology cisplatin Cisplatin - administration & dosage Cisplatin - therapeutic use Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives doxorubicin Doxorubicin - therapeutic use Female gemcitabine plus cisplatin Humans Male methotrexate Methotrexate - therapeutic use Middle Aged Multicenter Studies as Topic - statistics & numerical data muscle invasion Muscle Neoplasms - drug therapy Muscle Neoplasms - mortality Muscle Neoplasms - secondary neoadjuvant Neoadjuvant Therapy Neoplasm Invasiveness plus cisplatin Retrospective Studies Treatment Outcome Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology vinblastine Vinblastine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!